Cargando…

SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions

Nonalcoholic fatty liver disease (NAFLD) is increasingly recognized as a major expanding national and international health problem. Despite numerous investigations using a variety of therapeutic agents, the positive result on any single medication has not been established enough to gain widespread a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gharaibeh, Naser Eddin, Rahhal, Marie-Noel, Rahimi, Leili, Ismail-Beigi, Faramarz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6613609/ https://www.ncbi.nlm.nih.gov/pubmed/31308716 http://dx.doi.org/10.2147/DMSO.S212715

Ejemplares similares

Glucocorticoid-Induced Fatty Liver Disease
por: Rahimi, Leili, et al.
Publicado: (2020)

Challenging Issues in the Management of Cardiovascular Risk Factors in Diabetes During the COVID-19 Pandemic: A Review of Current Literature
por: Rahimi, Leili, et al.
Publicado: (2020)

SGLT2 Inhibitors as the Most Promising Influencers on the Outcome of Non-Alcoholic Fatty Liver Disease
por: Mirarchi, Luigi, et al.
Publicado: (2022)

The effect of sodium-glucose co-transporter-2 (SGLT2) inhibitors on blood interleukin-6 concentration: a systematic review and meta-analysis of randomized controlled trials
por: Gohari, Sepehr, et al.
Publicado: (2023)

Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial
por: Taheri, Hoda, et al.
Publicado: (2020)

COVID-19 Vaccine and Hyperosmolar Hyperglycemic State
por: Abu-Rumaileh, Mohammed A, et al.
Publicado: (2021)

Pathophysiology of Non Alcoholic Fatty Liver Disease
por: Petta, Salvatore, et al.
Publicado: (2016)

The Mechanism of the Calorigenic Action of Thyroid Hormone : Stimulation of Na(+) + K(+)-activated adenosinetriphosphatase activity
por: Ismail-Beigi, Faramarz, et al.
Publicado: (1971)

Non-alcoholic fatty liver diseases: current challenges and future directions
por: Roeb, Elke
Publicado: (2021)

Therapeutic options in pediatric non alcoholic fatty liver disease: current status and future directions
por: Vajro, Pietro, et al.
Publicado: (2012)

SAT-483 Levothyroxine Absorption Test: A Potential Therapeutic Tool for Levothyroxine Malabsorption
por: Arora, Tanureet, et al.
Publicado: (2020)

Anorexia Nervosa and Osteoporosis: Pathophysiology and Treatment
por: Steinman, Jeremy, et al.
Publicado: (2019)

Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
por: Chehrehgosha, Haleh, et al.
Publicado: (2021)

Dual SGLT1/SGLT2 Inhibitor Phlorizin Ameliorates Non-Alcoholic Fatty Liver Disease and Hepatic Glucose Production in Type 2 Diabetic Mice
por: David-Silva, Aline, et al.
Publicado: (2020)

Pathophysiology of Depression: Stingless Bee Honey Promising as an Antidepressant
por: Zakaria, Fatin Haniza, et al.
Publicado: (2022)

Non-Alcoholic Fatty Liver Disease and Cardiovascular Comorbidities: Pathophysiological Links, Diagnosis, and Therapeutic Management
por: Jichitu, Alexandra, et al.
Publicado: (2021)

Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects
por: Palmiero, Giuseppe, et al.
Publicado: (2021)

Pathophysiological basis of the cardiological benefits of SGLT-2 inhibitors: a narrative review
por: Panico, Cristina, et al.
Publicado: (2023)

Prolonged Exposure to Insulin Inactivates Akt and Erk(1/2) and Increases Pancreatic Islet and INS1E β-Cell Apoptosis
por: Rachdaoui, Nadia, et al.
Publicado: (2018)

Non-alcoholic Fatty Liver Disease and Steatohepatitis: Risk Factors and Pathophysiology
por: Akter, Sharmin
Publicado: (2022)

Pathophysiological mechanisms of cardiovascular disorders in non-alcoholic fatty liver disease
por: Garbuzenko, Dmitry Victorovich
Publicado: (2022)

Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options
por: Grander, Christoph, et al.
Publicado: (2023)

Nephroprotection by SGLT2 Inhibition: Back to the Future?
por: De Nicola, Luca, et al.
Publicado: (2020)

Role of MicroRNAs in Pathophysiology of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis
por: Iravani, Farzaneh, et al.
Publicado: (2018)

ARNI and SGLT2i: a promising association to be used with caution
por: Herbst, Andrea, et al.
Publicado: (2020)

High-Dose Liraglutide and SGLT2 Inhibitor: A Promising Combination
por: Chua, Marvin Wei Jie
Publicado: (2021)

Non-alcoholic fatty liver disease: controlling an emerging epidemic, challenges, and future directions
por: Ofosu, Andrew, et al.
Publicado: (2018)

Efficacy of SGLT2 Inhibitors Versus Pioglitazone in the Treatment of Non-alcoholic Fatty Liver Disease or Non-alcoholic Steatohepatitis: A Systematic Review
por: Kaur, Simran, et al.
Publicado: (2023)

Direct cardiac effects of SGLT2 inhibitors
por: Chen, Sha, et al.
Publicado: (2022)

Diabetes Mellitus and Heart Failure: Epidemiology, Pathophysiologic Mechanisms, and the Role of SGLT2 Inhibitors
por: Theofilis, Panagiotis, et al.
Publicado: (2023)

The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease
por: Perakakis, Nikolaos, et al.
Publicado: (2020)

Pathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets
por: Santos-Laso, Alvaro, et al.
Publicado: (2021)

Hepatokines and Non-Alcoholic Fatty Liver Disease: Linking Liver Pathophysiology to Metabolism
por: Kim, Tae Hyun, et al.
Publicado: (2021)

Non-alcoholic fatty liver disease in type 1 diabetes: Prevalence and pathophysiology
por: Memaj, Plator, et al.
Publicado: (2022)

Mitochondrial Targeting Therapeutics: Promising Role of Natural Products in Non-alcoholic Fatty Liver Disease
por: Xu, Jingqi, et al.
Publicado: (2021)

Cyclic vomiting syndrome: Pathophysiology, comorbidities, and future research directions
por: Hasler, William L., et al.
Publicado: (2019)

A Review of Sarcopenia Pathophysiology, Diagnosis, Treatment and Future Direction
por: Cho, Myung-Rae, et al.
Publicado: (2022)

Effect of Empagliflozin and Pioglitazone on left ventricular function in patients with type two diabetes and nonalcoholic fatty liver disease without established cardiovascular disease: a randomized single-blind clinical trial
por: Attaran, Fereshte, et al.
Publicado: (2023)

SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review
por: Raj, Henith, et al.
Publicado: (2019)

SGLT2 inhibitors in patients with type 2 diabetes with non-alcoholic fatty liver diseases: an umbrella review of systematic reviews
por: Shao, Shih-Chieh, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_n6a68me5rmr5u7bac0i9o6k60k